Joshua Robak, MD

Research reveals that IV haloperidol and ziprasidone are safe for treating delirium in patients that are critically ill, showing minimal impact on QTc intervals.

This randomized, placebo-controlled, phase 3 clinical trial showed that a 14-day treatment course of oral zuranolone 50 mg/day in MDD led to significantly greater improvements in depressive symptoms when compared with placebo.

A fourth-year medical student at the University of North Dakota and member of the Climate Psychiatry Alliance writes about his concerns regarding climate effects on health.